Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Developing innovative technology for the low-cost conversion of abundant biomass. Private 2006 View Profile
<a href="/venture-capital/all-companies/moderna">moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> Providing XFe Analyzers and stress test kits that are becoming the industry standard in cell metabolism measurements. Private 2001 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Pioneering the development of Systems Diagnostics (SysDx(TM)). Private 2001 View Profile
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Developing activity-based costing systems for healthcare providers. Private 2010 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming global nutrition. Private 2010 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Pioneering a new class of therapeutics that, for the first time, catalyzes health in multiple important therapeutic areas. Private 2012 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Commercializing chemical catalysts for upgrading waste biomass to fuels, chemicals, and materials. Private 2010 View Profile
<a href="/venture-capital/all-companies/aerodesigns-inc">AeroDesigns Inc.</a> Pioneering air-based delivery systems to reimagine the consumption of food, nutrients and medications. Private 2011 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. Public 2000 View Profile
<a href="/venture-capital/all-companies/helicos-biosciences-corporation">Helicos BioSciences Corporation</a> Innovative genetic analysis technologies for the development and marketing of molecular diagnostics tests. Public 2003 View Profile
<a href="/venture-capital/all-companies/receptos-inc">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. Public 2009 View Profile
<a href="/venture-capital/all-companies/tetraphase-pharmaceuticals-inc">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. Public 2006 View Profile